Abstract:You have accessJournal of UrologyInfections/Inflammation of the Genitourinary Tract: Interstitial Cystitis1 Apr 2014PD9-02 TRANSGENIC MICE THAT SECRETE MCP-1 BY THE UROTHELIUM DEMONSTRATE BLADDER HYPERSENSITIVITY, PELVIC PAIN AND URINARY SYMPTOMS Yi Luo, Liwei Liu, Xu Wang, Michael O'Donnell, and Karl Kreder Yi LuoYi Luo More articles by this author , Liwei LiuLiwei Liu More articles by this author , Xu WangXu Wang More articles by this author , Michael O'DonnellMichael O'Donnell More articles by this author , and Karl KrederKarl Kreder More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.784AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Excessive production of monocyte chemotactic protein-1 (MCP-1) has been observed in various inflammatory, chronic pain, and bladder overactive conditions. We have observed that over half of patients with interstitial cystitis/bladder pain syndrome (IC/BPS) express elevated MCP-1 in the urine. This study was to develop a mouse model that secretes MCP-1 by the urothelium to facilitate the study of IC/BPS in humans. METHODS A 4.9 Kb transgene consisting of the uroplakin II gene promoter and mouse MCP-1 coding sequence with a secretory element was constructed and microinjected for developing a MCP-1 secreting transgenic mouse line (URO-MCP-1). Mice were screened by tail genotyping and backcrossed onto the C57BL/6 genetic background. RT-PCR was used to assess MCP-1 mRNAs in the bladder and ELISA used to assess MCP-1 protein in the urine. To induce bladder inflammation, lipopolysaccharide (LPS) was administered intravesically. Bladder inflammation was analyzed by histological hematoxylin and eosin (H&E). Von Frey filament stimulation was used to assess pelvic pain and micturition cages used to assess voiding dysfunction. Cadi-05, a novel Toll-like receptor modulator, was intradermally administered once daily for total three doses starting one day before cystitis induction up to day 1. The bladders were analyzed by histological H&E staining at day 2. RESULTS URO-MCP-1 mice express MCP-1 mRNA in the bladder but not in other organs. Urine contains ∼1,500 pg/ml of MCP-1. While the bladders of URO-MCP-1 mice were normal in the unmanipulated state, they exhibited a much lower threshold trigger for producing exaggerated responses to otherwise sub-noxious inflammatory stimuli such as LPS. Compared to control C57BL/6 mice, URO-MCP-1 mice exhibited clear histological bladder inflammation with intensive edema and cellular infiltration 24 hours after intravesical instillation of even a single low does of LPS (1 μg in 100 μl). The bladder inflammation peaks at days 1-3 and lasts 5-7 days. URO-MCP-1 mice exhibited pelvic pain and increased urinary frequency and decreased urine output per void after cystitis induction (p<0.05). Intradermal Cadi-05 treatment significantly reduced bladder histopathology (p<0.01). CONCLUSIONS The URO-MCP-1 model exhibits key symptomatology of IC/BPS and is responsive to intradermal Cadi-05 therapy. This model offers a unique translational opportunity for investigation of the pathological mechanisms and therapeutic development for the human disease. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e212 Advertisement Copyright & Permissions© 2014Metrics Author Information Yi Luo More articles by this author Liwei Liu More articles by this author Xu Wang More articles by this author Michael O'Donnell More articles by this author Karl Kreder More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Aberrant Expression of Monocyte Chemoattractant Protein-1 (Mcp-1) in Interstitial Cystitis Patients

Expression of Monocyte Chemoattractant Protein-1 in the Interstitial Cystitis Patients

UP-2.032: Aberrant Expression of Monocyte Chemoattractant Protein-1 (MCP-1) in Interstitial Cystitis Patients

Study on the Expression and Mechanism of Monocyte Chemoattractant Protein-1 in Interstitial Cystitis Rats

Diagnostic potential of urinary monocyte chemoattractant protein-1 for Alzheimer's disease and amnestic mild cognitive impairment

Number increase of Cajal interstitial cells in bladder of rats with recurrent cystitis

PD9-02 TRANSGENIC MICE THAT SECRETE MCP-1 BY THE UROTHELIUM DEMONSTRATE BLADDER HYPERSENSITIVITY, PELVIC PAIN AND URINARY SYMPTOMS

Transgenic Mice Expressing MCP-1 by the Urothelium Demonstrate Bladder Hypersensitivity, Pelvic Pain and Voiding Dysfunction: A Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network Animal Model Study

MCP-1-induced histamine release from mast cells is associated with development of interstitial cystitis/bladder pain syndrome in rat models.

Expression of Monocyte Chemoatractant Protein 1 in Colonic Mucosa of Patients with Ulcerative Colitis.

[Expression of MCP-1 in Renal Tissues of Patients with IgA Nephropathy].

Expression of Programmed Death Ligand-1 on Bladder Tissues is Detected in a Clinically and Histologically Well-Defined Interstitial Cystitis Cohort.

Monocyte Chemoattractant Protein-1 Expression in Renal Tissue is Associated with Monocyte Recruitment and Tubulo-Interstitial Lesions in Patients with Lupus Nephritis.

Study on the Level of Urine MCP-1 and Cellular Immunity and the Relativity Between Them

The changes and clinical significance of monocyte chemoattractant protein-1 in iga nephropathy

Combined Signature of the Urinary Microbiome and Metabolome in Patients With Interstitial Cystitis

Multimodal Single‐Cell Analyses Outline the Immune Microenvironment and Therapeutic Effectors of Interstitial Cystitis/Bladder Pain Syndrome

Increased expression of TNF ligand-related molecule 1A and death receptor 3 in bladder tissues of patients with painful bladder syndrome/interstitial cystitis.

Integrating single-cell RNA sequencing with spatial transcriptomics reveals immune landscape for interstitial cystitis

Identification of Key Genes in Human Urothelial Cells Corresponding to Interstitial Cystitis/bladder Pain Syndrome in a Lipopolysaccharide-Induced Cystitis Model.

Expression of Monocyte Chemoattractant Protein-1 in Lupus Nephritis and Its Clinical Significance